Possibilities and prospects of oral semaglutide therapy

Koteshkova O.M., Antsiferova D.M., Romashkina L.P., Antsiferov M.B.

1) Endocrinology Dispensary, Moscow Healthcare Department, Moscow, Russia; 2) Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Objective: Scientific review of current approaches to treating patients with type 2 diabetes mellitus (DM2) using the oral GLP-1 receptor agonist (GLP-1 RA) semaglutide.
Key points: Treatment of diabetes mellitus is a pressing issue in modern medicine. New formulations of GLP-1 RA are emerging, making therapy more acceptable to patients. In 2025, PROMOMED introduced Semaltara®, an oral formulation of semaglutide, in various therapeutic doses (3 mg, 7 mg, and 14 mg), which is widely used in clinical practice.
Conclusion: Current approaches to the treatment of type 2 diabetes mellitus recommend the use of semaglutide, including in oral form, both to improve carbohydrate metabolism and to reduce the risk of developing and progressing cardiovascular diseases (CVD), chronic kidney disease (CKD), as well as in the presence of atherosclerotic CVD (ASCVD) or risk factors for it, CKD, and obesity in patients.

For citations: Koteshkova O.M., Antsiferova D.M., Romashkina L.P., Antsiferov M.B. Possibilities and prospects of oral semaglutide therapy. Pharmateca. 2026;33(2):30-38. (In Russ.). DOI: https://dx.doi.org/10.18565/pharmateca.2026.2.30-38

Authors’ contribution: M.B. Antsiferov – article design, manuscript approval. O.M. Koteshkova – review of publications on the topic of the article, manuscript writing. D.M. Antsiferova – review of publications on the topic of the article, writing the manuscript. L.P. Romashkina – review of publications on the topic of the article, writing the manuscript.
Conflicts of interest: The authors confirm that they have no conflicts of interest to declare.
Funding: The study was conducted without any sponsorship.

Keywords

About the Authors

Olga M. Koteshkova, Cand. Sci. (Med.), Head of the Department of Diabetes Education and Treatment, Endocrinology Dispensary, Moscow Healthcare Department, Moscow, Russia; koala58@mail.ru, ORCID: https://orcid.org/0000-0001-8428-4116, eLibrary SPIN: 6141-1224 (corresponding author)
Daria M. Antsiferova, Endocrinologist, Endocrinology Dispensary, Endocrinology Dispensary, Moscow Healthcare Department, Moscow, Russia; Postgraduate Student, Department of Endocrinology, Russian Medical Academy of Continuous Professional Education, Moscow, Russia;
cifrenda@yandex.ru, ORCID: https://orcid.org/0000-0002-3920-5914, eLibrary SPIN: 5461-2590
L.P. Romashkina, Endocrinology Dispensary, Endocrinology Dispensary, Moscow Healthcare Department, Moscow, Russia
Mikhail B. Antsiferov, Dr. Sci. (Med.), Professor, President, Endocrinology Dispensary, Moscow Healthcare Department; Professor, Department of Endocrinology, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; antsiferov@rambler.ru, ORCID: https://orcid.org/0000-0002-9944-2997, eLibrary SPIN: 1035-4773

Similar Articles